drugset / Trial / NCT06380751
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Timeline
- Start
- 2024-08-01
- Primary completion
- 2029-12-18
- Completion
- 2031-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Anastrozole | Other / unclassified | — | Oral |
| Subject | Camizestrant | Other / unclassified | — | Oral |
| Subject | Exemestane | Small molecule | — | Oral |
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | Oral |
| Subject | Saruparib | Small molecule | — | Oral |